ArticleTherapeutic advances in gastroenterology2026
Exclusive enteral nutrition and infliximab combination therapy are superior to monotherapy in inducing endoscopic response in active adult Crohn's disease.
Article in Therapeutic advances in gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Anti-tumor necrosis factor alpha (anti-TNFα) agents assume a significant role in the management of Crohn's disease (CD). Exclusive enteral nutrition (EEN) is as effective as corticosteroids for inducing remission in children with active CD, but less effective in adults. Few studies have compared the relative effectiveness of these strategies in achieving endoscopic improvement and symptom relief. Objectives: We aimed to compare the efficacy of EEN, infliximab (IFX), and combination therapy in adult patients with CD. Design: Retrospective cohort study. Methods: Between March 2021 and June 2024, 270 adult patients with active CD were recruited and received EEN, IFX, or combination treatment for 14 weeks. Propensity-score (PS) matching was conducted to balance the baseline characteristics across the three groups. The fecal 16S rRNA sequencing and metabolomics analyses were applied to further analyze the underlying mechanism involved in combination and monotherapy. Results: Of the 270 reviewed patients, a total of 146 PS-matched adult CD patients who received EEN ( Conclusion: Combination therapy is more effective than EEN or IFX monotherapy for short-term endoscopic and clinical response. Mechanistically, combination therapy reshapes the gut microbiota, restores levels of SCFAs, and increases key protective fecal metabolites, offering a promising strategy for the management of CD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.